Management of type 2 diabetes is very complex as well as challenging. SGLT2 Inhibitors is a novel class of oral glucose-lowering therapy which recently become popular as a treatment option for T2DM.

It reduces the reabsorption of glucose in the kidney and increases its excretion via the urine. This exclusive KOL Interview gives valuable insights into SGLT2 inhibitors and diabetes management.